By What Are GLP-1 Drugs?
GLP-1 drugs (glucagon-like peptide-1 receptor agonists) were originally developed to treat type 2 diabetes. They work by mimicking a natural hormone that regulates blood sugar, slows digestion, and reduces appetite. More recently, several have been approved or prescribed off-label for weight loss, which dramatically expanded their use.
The most common types of GLP-1 drugs on the market include:
- Semaglutide: Ozempic (diabetes), Wegovy (weight loss), Rybelsus (oral tablet) — Novo Nordisk
- Tirzepatide: Mounjaro (diabetes), Zepbound (weight loss) — Eli Lilly
- Dulaglutide: Trulicity — Eli Lilly
- Liraglutide: Victoza (diabetes), Saxenda (weight loss) — Novo Nordisk
- Exenatide: Byetta, Bydureon BCise — AstraZeneca
Ozempic and Wegovy are at the center of the most GLP-1 lawsuits filed to date, largely because of their widespread use and the severity of gastrointestinal injuries reported by patients.
What Is the GLP-1 Lawsuit About?
The GLP-1 lawsuit is a wave of personal injury and product liability cases alleging that pharmaceutical manufacturers knew their drugs could cause severe, permanent gastrointestinal damage but failed to properly warn patients or doctors. Core allegations include:
- Companies knew GLP-1 drugs could cause serious stomach and intestinal injuries
- They failed to include adequate warnings on drug labels
- They aggressively marketed these drugs for weight loss without disclosing full risks
- Patients suffered irreversible harm as a direct result
Ozempic Lawsuit
The Ozempic lawsuit is the highest-profile GLP-1 case. Approved by the FDA in 2017 for diabetes, Ozempic exploded in popularity as a weight-loss drug. Patients have since reported extreme nausea, uncontrollable vomiting, gastroparesis (stomach paralysis), and abdominal pain severe enough to require hospitalization or surgery. Plaintiffs allege Novo Nordisk understated or omitted these risks from the drug label.
Wegovy and Mounjaro Lawsuits
Wegovy (higher-dose semaglutide for weight loss) and Mounjaro/Zepbound (tirzepatide by Eli Lilly) face similar allegations. Many Wegovy plaintiffs had no diabetes diagnosis they were prescribed the drug purely for weight management and suffered serious gastrointestinal conditions as a result.
Serious Side Effects Behind the GLP-1 Drug Lawsuits
The lawsuits focus on injuries patients say were never disclosed to them:
- Gastroparesis the stomach muscles slow or stop working, causing chronic nausea, vomiting, bloating, and pain. For many patients this condition is permanent.
- Intestinal obstruction and ileus bowel blockages requiring emergency treatment or surgery
- Pancreatitis inflammation of the pancreas, a known but allegedly under-warned risk
- Severe vomiting and dehydration beyond the mild nausea listed as a common side effect
- Aspiration risk during surgery because GLP-1 drugs slow digestion, food may remain in the stomach even after standard pre-surgery fasting, creating a dangerous aspiration risk
- Thyroid tumor risk GLP-1 drug labels carry a black-box warning about thyroid C-cell tumors, which some lawsuits allege was buried or insufficient
Who Can File a GLP-1 Lawsuit?
You may be eligible if you took an Ozempic, Wegovy, Mounjaro, or another GLP-1 drug and suffered a serious, documented medical injury such as gastroparesis, pancreatitis, or intestinal obstruction. You do not need to have used the drug for years some patients report serious harm after just weeks. Diabetic patients who took GLP-1 drugs for their intended use can also file.
People who experienced only mild side effects that resolved on their own are unlikely to qualify. Cases involving compounded (pharmacy-made) versions of these drugs may also face additional legal hurdles.
What Damages Can You Recover?
A successful GLP-1 drug lawsuit may entitle you to compensation for medical expenses, lost wages, loss of earning capacity, pain and suffering, loss of enjoyment of life, and in some cases punitive damages where manufacturer conduct was especially reckless.
What Should You Do Now?
- See a doctor and make sure your injury is documented in your medical records
- Keep all prescription records, pharmacy receipts, and hospital paperwork
- Do not discard the drug packaging lot numbers can be key evidence
- Contact a GLP-1 lawsuit attorney for a free consultation (most work on contingency no fee unless you win)
- Report your experience to the FDA via their MedWatch program at fda.gov/safety/medwatch
Statutes of limitations apply. Deadlines are typically two to three years from when you knew your injury was linked to the drug, and they vary by state. Do not delay.
The Bottom Line
GLP-1 drugs have helped millions manage diabetes and weight. But for too many patients, these medications have caused serious, life-altering harm that was never disclosed. The GLP-1 drug lawsuit is about accountability making pharmaceutical companies answer for what patients say they hid.
If you were harmed by Ozempic, Wegovy, Mounjaro, or another GLP-1 drug, speak with a qualified attorney as soon as possible. Time limits apply, and your rights matter.
Frequently Asked Questions
Q1: Can I still file if I stopped taking the drug over a year ago?
Yes, in most states. The clock typically starts when you discovered (or reasonably should have discovered) your injury was connected to the drug not when you stopped taking it. Speak with an attorney to confirm your state’s deadline.
Q2: Do I need a gastroparesis diagnosis specifically?
No. Other serious conditions such as pancreatitis, intestinal obstruction, or severe vomiting requiring hospitalization may also qualify. What matters is that your injury was medically documented and caused real harm.
Q3: What is the difference between the GLP-1 class action lawsuit and MDL?
Most GLP-1 cases are filed as individual personal injury lawsuits and grouped into multidistrict litigation (MDL) for efficiency not a single class action where everyone gets the same payout. In MDL, each plaintiff has their own case and their own potential recovery.
Q4: Does it cost money to file a GLP-1 lawsuit?
Most mass tort attorneys handle these cases on contingency you pay nothing upfront and no legal fees unless you win. Initial consultations are typically free.
Q5: Have there been any settlements yet?
As of early 2025, no large global settlements have been publicly announced. Litigation is still in the discovery and early trial phase. Settlements often emerge after bellwether trials give both sides a clearer picture of jury outcomes.